tradingkey.logo

AIM ImmunoTech Inc

AIM
View Detailed Chart

2.680USD

+0.070+2.68%
Close 09/19, 16:00ETQuotes delayed by 15 min
2.05MMarket Cap
LossP/E TTM

AIM ImmunoTech Inc

2.680

+0.070+2.68%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.68%

5 Days

+3.08%

1 Month

+6.77%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

TradingKey Stock Score

No scoring data

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Ticker SymbolAIM
CompanyAIM ImmunoTech Inc
CEOMr. Thomas K. Equels, Esq., J.D.
Websitehttps://aimimmuno.com/
KeyAI